About Us
Advancing the Future of Diagnosis
Driven by science, guided by patients, and built for global impact
At ALZpath, we’re focusing on what it takes to move Alzheimer’s diagnosis out of specialized clinics and into routine care. That means making it easier to detect the disease early – well before symptoms take hold and while people still have options.
Our proprietary pTau217 antibody is used by diagnostic leaders around the world to develop blood tests that detect Alzheimer’s disease pathology quickly, accurately, and at scale.
This shift – from late, invasive diagnosis to early, blood-based detection – is already underway. We are one of the reasons it’s happening.
Our Mission
ALZpath delivers early and accurate detection of Alzheimer’s disease through a simple blood test – helping clarify diagnosis today and advancing the future of prevention and treatment.
“We are relentless in our drive to help people understand their risk for Alzheimer's disease and give them the time to act.”
-CEO Mike Banville
Our Leadership Team
Meet the team leading our scientific, clinical, and strategic efforts to drive earlier detection and better outcomes. Focused, relentless, and driven by results, we build the tools and partnerships needed to shift Alzheimer’s disease diagnosis earlier to make a real difference.
CEO and President
Chief Financial Officer
Chief Business Officer
VP of Research & Development
Our Board of Directors
Our Board brings experience in company building, scaling diagnostics, and navigating complex markets to help guide our mission and expand its impact.
Our Advisory Board
Our Advisory Board is composed of many of the field’s most distinguished leaders and clinical experts in Alzheimer’s disease and other neurological conditions. Their guidance strengthens our science and accelerates our progress.
Distinguished Scientific Advisor
Vice Chair
Co-Founder
Connect With Us
If you’re building the future of Alzheimer’s diagnostics – whether you’re developing a test, designing a clinical trial, or diagnosing and treating patients – we should talk.
